Cardiff Oncology, Inc. - Common Stock — Quarterly Financial Statistics (NASDAQ:CRDF) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -12.79 M-8.33 M-10.83 M-5.97 M-12.29 M-11.77 M -40.85 M Cash from investing activities -14.58 M-4.98 M10.16 M10.75 M3.26 M12.27 M 36.44 M Cash from financing activities 3 000025 K2.55 M105 K149 K 2.83 M Free cash flow -12.79 M-8.33 M-10.85 M-5.97 M-12.29 M-11.77 M -40.87 M

News

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Slideshow (NASDAQ:CRDF) 2026-06-07

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript

Wall Street Lunch: BP Slips After Ousting Chairman Albert Manifold Over Governance Concern

5 Healthcare Stocks Set to Join the Russell 3000 - TipRanks.com

Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology Stock: Market Dismisses Onvansertib's Potential In Colorectal Cancer

Cardiff Oncology earnings beat by $0.08, revenue topped estimates

H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Why Did Cardiff Oncology Stock Plunge On Tuesday? - Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology stock tumbles after Phase 2 trial data update

Cardiff Oncology appoints interim CEO amid leadership transition